Status:

COMPLETED

Low Dosage of rt-PA in the Treatment of Pulmonary Thromboembolism in China

Lead Sponsor:

Beijing Chao Yang Hospital

Conditions:

Pulmonary Embolism

Thromboembolism

Eligibility:

All Genders

18-75 years

Phase:

PHASE4

Brief Summary

Recombinant tissue plasminogen activator (rt-PA) is currently the most commonly used thrombolytic drug in patients with pulmonary thromboembolism (PTE). Optimal dosing with maximal benefits and minima...

Detailed Description

Pulmonary thromboembolism (PTE) is a severe and common clinical problem with substantial morbidity and mortality both in US and in Europe. Used to be considered as a rare disease in China, PTE has bee...

Eligibility Criteria

Inclusion

  • age between 18 and 75
  • symptomatic PE confirmed by: a high probability ventilation-perfusion lung scanning (V/Q scan) or the presence of intraluminal filling defect on spiral computed tomographic pulmonary angiography (CTPA)
  • PTE patients with haemodynamic instability, or cardiogenic shock
  • anatomic obstruction more than 2 lobes on CTPA, or defect more than 7 segments on V/Q scan combined with evidence of right ventricular dysfunction(RVD) and pulmonary hypertension on echocardiography
  • written informed consent

Exclusion

  • active bleeding or spontaneous intracranial hemorrhage
  • major surgery, organ biopsy or recent puncture of a non-compressible vessel less than 10 days
  • cerebral arterial thrombosis within 2 months
  • gastro-intestinal bleeding within 10 days
  • major trauma within the past 15 days
  • neurosurgery or ophthalmologic operation with 30 days
  • uncontrolled hypertension (systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \> 110 mmHg)
  • recent external cardiac resuscitation manoeuvres
  • platelet count \< 100 000/mm3 at admission
  • pregnancy, puerperium or lactation with 2 weeks
  • infectious pericarditis or endocarditis
  • severe hepatic and kidney dysfunction
  • hemorrhagic retinopathy due to diabetes
  • a known bleeding disorder

Key Trial Info

Start Date :

June 1 2002

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2006

Estimated Enrollment :

118 Patients enrolled

Trial Details

Trial ID

NCT00781378

Start Date

June 1 2002

End Date

February 1 2006

Last Update

October 29 2008

Active Locations (23)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 6 (23 locations)

1

Beijing Chaoyang Hospital, Capital University of Medical Sciences

Beijing, Beijing Municipality, China, 100020

2

Beijing University People's Hospital

Beijing, Beijing Municipality, China

3

Peking Union Hospital, Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China

4

The Omni-hospital of Air-force

Beijing, Beijing Municipality, China